Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions

Harvard Review of Psychiatry

Volumn 23, Issue 2, 2015, Pages 63-75

  Connery, Hilary Smith ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Buprenorphine; Medication assisted treatment; Methadone; Naltrexone; Opioid use disorder

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANTAGONIST;

ALGORITHM; CLINICAL PRACTICE; DRUG INDICATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; TORSADE DES POINTES; FEMALE; FORECASTING; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNITED STATES;

BUPRENORPHINE; FEMALE; FORECASTING; HUMANS; MALE; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 84925357081     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000075     Document Type: Review

References (124)

1. th ed. Arlington, VA: APA, 2013.
2. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011:60:1487-92.
3. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: SAMHSA, 2013. http://www.samhsa.gov/data/sites/default/files/NSDUHnationalfindingresults2012/NSDUHnationalfindingresults2012/NSDUHresults2012.pdf
4. Executive Office of the President of the United States. Epidemic: responding to America's prescription drug abuse crisis. 2011. http://publications.iowa.gov/12965/1/NationalRxAbusePlan2011.pdf
5. Bailey JE, Campagna E, Dart RC; RADARS System Poison Center Investigators. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med 2009;53:419-24.
6. Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) System. J Am Acad Child Adolesc Psychiatry 2013;52:196-204.
7. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 2014;104:816-21.
8. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies - tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6.
9. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-66.
10. Hill KP, Rice LS, Connery HS, Weiss RD. Diagnosing and treating opioid dependence. J Fam Pract 2012;61:588-97.
11. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31:207-25.
12. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO, 2009.
13. Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology 2006;189:297-306.
14. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994;54:1215-28.
15. Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther 2014;348:217-26.
16. Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol 2008;605:486-91.
17. Pilgrim JL,McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Sci Int 2013;226:216-22.
18. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
19. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XRNTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108:1628-37.
20. Diaz A, Pazos A, Florez J, Ayesta FJ, Santana V, Hurle MA. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience 2002;112:345-53.
21. Volpe DA, McMahon Tobin GA, et al. Uniform assessment and ranking of opioidmu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011;59:385-90.
22. Yuan Y, Zaidi SA, ElbegdorjO, et al. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. J Med Chem 2013;56:9156-69.
23. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-13.
24. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl JMed 2003;349:949-58.
25. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238-46.
26. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008;300:2003-11.
27. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3): CD002209.
28. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007;26:405-10.
29. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 2006;32:503-17.
30. Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treatedwith oral or implant naltrexone for problematic opiate use. Addiction 2012;107:1817-24.
31. Degenhardt L, Larney S, Kimber J, Farrell M, Hall W. Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug Alcohol Rev 2014 Oct 10 [Epub ahead of print].
32. Dunn K, DeFulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychol Addict Behav 2014 Aug 18 [Epub ahead of print].
33. Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev 2014;33:115-28.
34. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010;304:1576-83.
35. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo ormethadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207.
36. DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend 2012;120:48-54.
37. Everly JJ, DeFulio A, KoffarnusMN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011;106:1309-18.
38. Thompson G, Kelly E, Christopoulos A, Canals M. Novel GPCR paradigms at the mu-opioid receptor. Br J Pharmacol 2015;172:287-96.
39. Williams JT, Ingram SL, Henderson G, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013;65:223-54.
40. Birdsong WT, Arttamangkul S, Clark MJ, et al. Increased agonist affinity at the mu-opioid receptor induced by prolonged agonist exposure. J Neurosci 2013;33:4118-27.
41. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012;15 (3 suppl):ES67-92.
42. Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from ameta-analysis. Pharmacogenomics 2013;14:813-24.
43. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012;121:189-204.
44. Grecksch G, Bartzsch K, Widera A, Becker A, Hollt V, Koch T. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology 2006;186:177-84.
45. Hajj A, Khabbaz L, Laplanche JL, Peoc'h K. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics 2013;14:575-85.
46. Dennis BB, Bawor M, Thabane L, Sohani Z, Samaan Z. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One 2014;9:e86114.
47. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006;20 suppl 1:s3-8.
48. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A current perspective. West J Med 1990;152:588-99.
49. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79-87.
50. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013;12:CD006318.
51. Woody G, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 2014;66:288-93.
52. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest 2003;33:824-9.
53. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011;(8):CD004145.
54. Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend 2014;139:79-85.
55. Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. Drug Alcohol Depend 2013;133:376-82.
56. Meade CS,Weiss RD, Fitzmaurice GM, et al. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr 2010;55:65-72.
57. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013;128:71-6.
58. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-109.
59. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012;107:1057-65.
60. Palmateer N, Hutchinson S, McAllister G, et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat 2014;21:25-32.
61. Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014;109:2053-9.
62. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapywith lower incidence of hepatitisC virus infection in young adult injection drug users. JAMA Intern Med 2014;174:1974-81.
63. Wikner BN, Ohman I, Selden T, Druid H, Brandt L, Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug Alcohol Rev 2014;33:491-8.
64. Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med 2014;174:796-801.
65. Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain 2014;15:338-65.
66. Zlotorzynska M, Milloy MJ, Richardson L, et al. Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility. Int J Drug Policy 2014;25:736-9.
67. Darke S. Opioid overdose and the power of old myths: what we thought we knew, what we do know and why it matters. Drug Alcohol Rev 2014;33:109-14.
68. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 2013;44:241-7.
69. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999;94:961-72.
70. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med 2014;15:1911-29.
71. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One 2013;8:e60600.
72. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:101-5.
73. Ritter AJ. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust N Z J Psychiatry 2002;36:224-8.
74. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs 2012;73:991-7.
75. McNicholas LF, Holbrook AM, O'Grady KE, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction 2012;1:91-7.
76. Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med 2010;4:211-6.
77. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-1998. Pharmacoepidemiol Drug Saf 2000;9:S24.
78. Pani PP, Trogu E, Maremmani I, Pacini M. QTc interval screening for cardiac risk inmethadone treatment of opioid dependence. Cochrane Database Syst Rev 2013;6:CD008939.
79. Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 2007;91:187-94.
80. Cohier C, Chevillard L, Risede P, Roussel O, Megarbane B. Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats. Toxicol Lett 2014;228:75-84.
81. Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006;26:274-83.
82. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 2011;118:326-34.
83. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91:269-78.
84. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse 2011;37:1-11.
85. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012;1:5-27.
86. Gower S, Bartu A, Ilett KF, Doherty D, McLaurin R, Hamilton D. The wellbeing of infants exposed to buprenorphine via breastmilk at 4 weeks of age. JHumLact 2014;30:217-23.
87. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2013;42:517-26.
88. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadoneversus buprenorphine-exposed neonates. Addiction 2012;1:53-62.
89. Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012;1:36-44.
90. Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012;1:63-73.
91. Kaltenbach K, Finnegan LP. Developmental outcome of children born tomethadonemaintainedwomen: a reviewof longitudinal studies. Neurobehav Toxicol Teratol 1984;6:271-5.
92. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009;104:1193-200.
93. Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse 2012;38:187-99.
94. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend 2014;136:21-7.
95. Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict 2013;22:574-80.
96. Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit CareMed 2011;12:e102-7.
97. Keen J, Oliver P, Rowse G, Mathers N. Residential rehabilitation for drug users: a review of 13 months' intake to a therapeutic community. Fam Pract 2001;18:545-8.
98. Kosten TR, Gorelick DA. The Lexington narcotic farm. Am J Psychiatry 2002;159:22.
99. McHugh RK, Murray HW, Hearon BA, et al. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Am J Addict 2013;22:18-22.
100. Warden D, Subramaniam GA, Carmody T, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav 2012;37:1046-53.
101. Mayet S, FarrellM, FerriM, Amato L, DavoliM. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005;(1):CD004330.
102. Masson CL, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 2004;99:718-26.
103. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001;68:62-74.
104. Soyka M. Opioids and traffic safety - focus on buprenorphine. Pharmacopsychiatry 2014;47:7-17.
105. Rapeli P, Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol 2011;11:13.
106. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-25.
107. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007;27:507-12.
108. Heinrich CJ, Cummings GR. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment. Health Serv Res 2014;49:127-52.
109. Lang K, Neil J, Wright J, Dell CA, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy 2013;8:8-35.
110. Fiellin DA, O 'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001;286:1724-31.
111. Roux P, Michel L, Cohen J, et al. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health 2012;12:488.
112. Kahan M, Wilson L, Midmer D, Ordean A, Lim H. Short-term outcomes in patients attending a primary care-based addiction shared care program. Can Fam Physician 2009;55:1108-9.
113. Debelak K, Morrone WR, O ' Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - initial patient care and outcome data. Am J Addict 2013;22:252-4.
114. ToxNet. LactMed. 2014. http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm
115. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis 2013;32:68-78.
116. Shi J, Li SX, Zhang XL, et al. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. Am J Drug Alcohol Abuse 2009; 35:267-72.
117. Li SX, Shi J, Epstein DH, et al. Circadian alteration in neurobiology during 30 days of abstinence in heroin users. Biol Psychiatry 2009;65:905-12.
118. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005;62:1157-64.
119. Chartoff EH, Connery HS. It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol 2014;5:116.
120. Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol 2013;21:294-302.
121. Bisaga A, SullivanMA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat 2014;46:546-52.
122. Bisaga A, Sullivan MA, Cheng WY, et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend 2011;119:e23-9.
123. Tabatabai SM, Dashti S, Doosti F, Hosseinzadeh H. Phytotherapy of opioid dependence and withdrawal syndrome: a review. Phytother Res 2014;28:811-30.
124. Gao JL, Tu SA, Liu J, et al. An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine system in morphine-dependent rats. BMC Complement Altern Med 2014;14:308.